Skip to content
DataLookout
Menu

NCT07421674

Assessing Hydromorphone Sustained-Release Tablets in Elderly Cancer Pain Patients With Renal Insufficiency

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Study description expanded, about 6 words
    • Site details revised
    • Publications: details revised at 18 of 18 entries
  2. Minor Study description expanded, about 4 wordsv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The changes in estimated glomerular filtration rate (eGFR) from baseline at the end of the 4th week of treatmentDetailed
Timeframe: From the start of maintenance treatment with hydromorphinone sustained-release tablets until the end of the fourth week of treatment.

Arms and interventions

Hydromorphone - Renal Insufficiency Group

Elder cancer pain patients with mild to moderate renal insufficiency at enrollment, defined by an estimated glomerular filtration rate (eGFR) range of 30 ≤ eGFR \< 90 mL/min/1.73m². They receive standardized Hydromorphone Sustained-Release Tablet treatment.

Hydromorphone - Normal Renal Function Group

Elder cancer pain patients with normal renal function at enrollment, defined by an estimated glomerular filtration rate (eGFR) of eGFR ≥ 90 mL/min/1.73m². They receive the identical standardized Hydromorphone Sustained-Release Tablet treatment as Cohort 1, serving as the reference comparison group.

Sites

1 site in 1 country

  • Tai'an Caner HospitalTai’an, Shandong, China